Original Post on lifescivoice.com and written by: Jeff Galvin It’s a tragic irony: So much money has been poured into treating diseases, but far less into actually curing them. The pharmaceutical industry has done an incredible job of developing highly profitable treatments for a wide range of diseases and conditions. Those treatments have generated trillions in revenue. But cures have… [Read More]
The Food and Drug Administration (FDA) recently approved the first injectable treatment for HIV pre-exposure prophylaxis (PrEP), which is critically important to prevent the spread of HIV, considering around 1.5 million people were newly infected with the disease in 2020. But ultimately, to end this epidemic and stop the suffering of nearly 38 million people currently living with HIV/AIDS worldwide,… [Read More]
Original Post on DNAWeekly and written by: Ditsa Keren American Gene Technologies (AGT) is a cutting-edge biotechnology company creating technologies that speed up the development of cures and treatments in the emerging field of gene therapy. In this interview, founder and CEO Jeff Galvin pinpoints the current challenges in drug development and offers a unique perspective on the future of medicine. Please describe… [Read More]
American Gene Technologies is celebrating a milestone in its HIV Cure Program, which is currently in Phase 1 human trial. The first participant, an unidentified man. ROCKVILLE, Md. – At a biotechnology company in Rockville, Md., a team of molecular biologists is working to develop cures for cancer, HIV, and a range of other diseases. American Gene Technologies (AGT) is… [Read More]
C. David Pauzaa, Kelly Huanga , and Jose Bordonb Purpose of review Tremendous advances in cell and gene therapy may soon realize the goal of treating and possibly curing HIV disease. These advances rely on new technologies for cell engineering and new strategies for product manufacturing that are targeting the most important immune deficits in HIV and promising to reconstitute… [Read More]
Published on: Bethesda Magazine | BY DAVID GOLDSTEIN Jeff Galvin believes his Rockville cell and gene technology company has found a breakthrough treatment for people living with HIV When Jeff Galvin was 13 years old, he came across a lone computer in the basement of Muzzey Junior High School in Lexington, Massachusetts. It was actually a teletype machine attached to a… [Read More]
Original Article: Molecular Therapy: Methods & Clinical Development Vol. 17 June 2020 Haishan Li,1 Tyler Lahusen,1 Lingzhi Xiao,1 Nidal Muvarak,1 Jana Blazkova,2 Tae-Wook Chun,2 and C. David Pauza1 1American Gene Technologies International, Rockville, MD, USA; 2Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, MD, USA Activation, infection, and eventual depletion of human immu- nodeficiency virus (HIV)-specific… [Read More]
The rapid growth of biopharma is causing a shift to a new paradigm for the drug development and delivery model. In the same manner that the personal computing industry grew and developed business models that fit the way products were sourced, constructed and delivered, a business model for biopharma is taking shape. Jeff Galvin, CEO of American Gene Technologies (AGT), had… [Read More]
Published by: Zacks Small Cap Research (SCR) | Written by: John Vandermosten, CFA Download The Full PDF American Gene Technologies (AGT) is a genetic medicines company developing a portfolio of therapies that employ the company’s proprietary lentiviral vector (LV) platform to focus on disease in areas of unmet medical need. AGT‘s pipeline consists of therapies for three different indications. The… [Read More]
Published by: Parenteral Drug Association (PDA), In: Volume LV, Issue 9 | Written by: Rebecca Stauffer Download The Full PDF What if developers of cell and gene therapies treated their products like software releases? What if the human body could be manipulated like a highly complex computer? Jeff Galvin, CEO of American Gene Technologies, certainly has that mindset, frequently referring to cell… [Read More]
Subscribe to our press release and published article updates to be notified when we release new content!
Subscribe to our newsletter to keep up to date with all the latest news about AGT!